This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Momentum in Integer (ITGR) Should Keep going
by Zacks Equity Research
Integer (ITGR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Integer (ITGR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Integer Holdings (ITGR) Beats on Q2 Earnings, Ups 2021 View
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust segmental performances along with strength in majority of the product lines.
Integer (ITGR) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 17.58% and 6.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Trinseo, Integer Holdings Corp, Telefonica and Eos Energy
by Zacks Equity Research
Zacks.com featured highlights include: Trinseo, Integer Holdings Corp, Telefonica and Eos Energy
4 Stocks to Keep an Eye on as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like TSE, ITGR, VIV and EOSE.
Integer (ITGR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks
by Zacks Equity Research
Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks
New Analyst Coverage Puts Spotlight on These 4 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like HIBB, ITGR, CERE and ATEN.
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
Integer (ITGR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Integer (ITGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Change Healthcare (CHNG) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance in the Network Solutions segment.
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
Glaukos (GKOS) Loses 14.3% Despite Narrower Loss in Q1
by Zacks Equity Research
Despite reporting first-quarter loss, Glaukos' (GKOS) results reflect rise in revenues.
Fresenius Medical (FMS) Gains 1.1% Since Q1 Earnings Beat
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from organic growth in Health Care Products segment, and performance in Asia Pacific.
LHC Group (LHCG) Loses 1.1% In Spite of Q1 Earnings Beat
by Zacks Equity Research
LHC Group's (LHCG) first-quarter results benefit from organic growth in hospice admissions.
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the first quarter.
Here's Why You Should Buy National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) backed by its improvement in comparable store sales (comps) in eyeglasses and contact lens.
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gains from segmental strength in the first quarter.
Nevro (NVRO) Stock Slips 2.9% Despite Narrower Loss in Q1
by Zacks Equity Research
Nevro's (NVRO) international revenues rise on a year-over-year basis in Q1.
McKesson (MCK) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses revenue growth in each of its segments in the first quarter.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q2
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.